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Abstract
Background: Host innate antiviral immunity is the first line of defense against viral infection, and is precisely
regulated by thousands of genes at various stages, including microRNAs. MicroRNA-155 (miR-155) was found to be
up-regualted during viral infection, and influence the host immune response. Besides, the expression of miR-155, or
its functional orthologs, may also contribute to viral oncogenesis. HBV is known to cause hepatocellular carcinoma,
and there is evidence that attenuated intracellular immune response is the main reason for HBV latency. Thus, we
assume miR-155 may affect the immune response during HBV infection in human hepatoma cells.
Results: We found that ectopic expression of miR-155 upregulated the expression of several IFN-inducible antiviral
genes in human hepatoma cells. And over-expression of miR-155 suppressed suppressor of cytokine signaling 1
(SOCS1) expression and subsequently enhanced signal transducers and activators of transcription1 (STAT1) and
signal transducers and activators of transcription3 (STAT3) phosphorylation. We further demonstrate that ectopic
expression of miR-155 inhibits HBV X gene expression to some extent in vitro.
Conclusion: MiR-155 enhances innate antiviral immunity through promoting JAK/STAT signaling pathway by
targeting SOCS1, and mildly inhibits HBV infection in human hepatoma cells.
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Background
MicroRNAs (miRNA) are a class of highly conserved
short noncoding RNAs originate from genome of eukar-
yotic organisms and even kinds of virus. MiRNAs have
emerged as a major class of post-transcriptional gene-
expression regulators and are involved in a wide variety
of biological processes. They regulate target gene
expression mainly through imperfectly base pairing with
the 3’ -untranslated regions (3’-UTRs) of target mRNAs
in animals, preventing protein accumulation by inducing
mRNA degradation or suppressing translation [1,2].
Recent researches demonstrate that many miRNAs,
such as miR-146a, miR-155 and miR-223, play impor-
tant roles in innate immune response at various phases
in vertebrates [3]. In order to eliminate virus immedi-
ately after infection, host-encoded miRNAs can directly
interfere in virus replication. Meanwhile, virus-encoded
miRNAs can not only evolve to regulate viral gene
expression to accommodate life cycle and maintain
latency [4], but also affect cellular gene expression by
directly participating in host gene expression or by
mimicking cellular miRNAs to hijack in unclear cellular
regulatory networks. So, research on the roles of
miRNA is an important pathway to reveal the “fighting”
between pathogenic microorganism and their hosts.
Among all miRNAs discovered in Homo sapiens in
miRBase Release 17, miR-155 is considered as one of
the typical multifunctional miRNAs. MiR-155 is first
found within the B cell integration cluster (BIC) on
chromosome 21 in human genome. The genomic struc-
ture of human BIC consists of three exons, and miR-155
is located within the third exon [5]. To date, increasing
evidence reveals that miR-155 is involved in numerous
physiological and pathological processes including innate
and adaptive immunity, inflammation and tumorigenesis
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any medium, provided the original work is properly cited.[6]. Moreover, miR-155 was found to be induced by
poly (I:C) and other TLR ligands through either MyD88
or TRIF dependent signaling pathways, and by IFN-b
and several cytokines such as IL-1b through TNF-a
signaling.
Viruses may downregulate the expression of certain
cellular miRNAs that are harmful for viral movement
and may also upregulate some miRNAs that are rational
for the virus. Although the benefit of miR-155 expres-
sion to viruses remains largely unknown, the expression
of miR-155, or its functional orthologs, may contribute
to viral oncogenesis, like KSHV [7] and MDV-1 [8]
encoding a viral miR-155 ortholog while EBV instead
induces expression of endogenous miR-155. However,
t i l ln o w ,t h e r ea r eo n l yaf e wr e p o r t sa b o u tt h er o l e so f
miR-155 in viral infection.
HBV, which causes acute and always chronic HBV
infection and leads to hepatoma fibrosis, cirrhosis and
eventually hepatocellular carcinoma [9], has infected
more than 350 million people and become a main threa-
ten to public health across the world, especially in devel-
oping countries [10]. Modern immunology believed that
impaired immune system, both intrinsic immune
response and classical humoral/cellular immunity is the
major reason for HBV latency, chronicity and reactivity,
and many achieves have been made to explain the mole-
cular mechanism upon this topic[11].
Based on all the outcomes have been made in this
field, we become interested in the roles of miRNA in
hepatocyte-HBV interactions. Though miR-155 level was
very low in normal hepatocytes and several hepatoma
cells lines, but it can be upregulated in certain patholo-
gical process, such as tumorigenesis. Considering that
HBV can promote carcinomatous change in hepatocyte,
it can be expected that miR-155 may be a unique mole-
cular in HBV pathopoiesis. But until now there is no
report about the role of miR-155 on the innate antiviral
immunity in human hepatocytes or hepatoma cells.
In the present study, miR-155 was over-expressed in
human hepatoma cells (HepG2, H7402), and we found
that SOCS1 expression was suppressed and subse-
quently the phosphorylation STAT1 and STAT3 were
enhanced, which resulted in the induction of IFN-indu-
cible genes expression. Additionally, over-expression of
miR-155 slightly increased the proliferation ability of
HepG2 cells, while exhibited mild anti-HBV effect in
human hepatoma cells. These findings reveal a new
intricate physiological interplay between miRNAs and
HBV replication.
Results
Over-expression of miR-155 in human hepatoma cells
To investigate the role of miR-155 in antiviral immune
response in human hepatoma cells, we used two
methods to over-express miR-155 in human hepatoma
cells [12,13]. First, the plasmid pcDNA3-hsa-miR-155
was transfected into HepG2 cells using Lipofectamine
2000, and these cells were selected by G418 for two
weeks. Levels of miR-155 in transfectant HepG2 cells
(HepG2-miR155) were evaluated by qRT-PCR. As
shown in Figure 1A, miR-155 level in HepG2-miR155
cells was significantly higher than that in parental
HepG2 cells (~ 40 folds) (P < 0.01). Next, miR-155
mimics or control RNA (cnt RNA) were transiently
transfected into HepG2 cells. As shown in Figure 1B,
Figure 1 Over-expression of miR-155 in human hepatoma cells.
(A) qRT-PCR analysis of miR-155 levels in miR-155 gene-modified
HepG2 (HepG2-miR155) cells and parental HepG2 cells. (B) 50 nM
miR-155 mimics or control RNA (cnt RNA) were transfected into
HepG2 cells. qRT-PCR analysis was performed 48 h after transfection.
Data shown are means ± SD from at least three separate
experiments. (*P < 0.05, **P < 0.01 by comparison with control
cells).
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miR-155 mimics was much higher (~ 2500 folds) than
that in HepG2 cells transfected with control RNA (P <
0.01).
miR-155 slightly increased the growth of human
hepatoma cells
MiR-155 has been reported to be over-expressed in
many solid tumor cells and functions as ‘oncomir’
[6,14]. So, we identified whether miR-155 could regulate
human hepatoma cell proliferation in vitro. Until cul-
tured for 4 days, it showed a slight increase in the pro-
liferation of miR-155 over-expressed HepG2 cells,
especially HepG2 cells transfected with miR-155 mimics,
when compared to that of control cells (Figure 2A and
2B), indicating that miR-155 displays different roles in
diverse cells.
Upregulation of IFN-inducible antiviral genes by miR-155
over-expression in human hepatoma cells
The type I interferon dependent cytokines are recognized
as crucial components during the innate immune response
and the first line of antiviral defense. In the studies of gene
knockout mice, ISG15, Mx proteins (MxA), 2’-5’ oligoade-
nylate synthetase (OAS) and APOBEC3 family, such as
APOBEC3B (A3B) have been validated as antiviral effec-
tors [15-17]. Therefore, the expression of MxA, ISG15,
OAS-1, A3B and interferon regulatory factor3 (IRF3) in
HepG2 cells were evaluated by RT-PCR (Figure 3A and
3C). We found that the mRNA levels of MxA and ISG15
in miR-155 over-expressed HepG2 cells were increased
about 30% and 40% respectively, while the levels of A3B,
OAS1 and IRF3 were not significantly changed (Figure 3B
and 3D). Similar results were observed in another human
hepatoma cell line H7402 (Figure 3E and 3F). Western
blot analysis showed that ISG15 protein levels were
increased as well (Figure 3G and 3H).
miR-155 post-transcriptionally regulated SOCS1 and
activated JAK/STAT signaling pathway in human
hepatoma cells
Earlier studies indicated that miR-155 and SOCS1 inter-
acted in regulatory T cells, macrophages and human
breast cancer cells [18-20]. SOCS1 has been identified
to negatively regulate various immune responses and
signaling pathways, including the IFN signaling [21,22].
Then we examined whether the translation level of
SOCS1 was regulated by miR-155 in human hepatoma
cells. Western blot assays indicated that the SOCS1 pro-
tein level was reduced significantly in HepG2 cells over-
expressing miR-155 compared with the relative control
(Figure 4B, D), while the mRNA level of SOCS1 was not
obviously changed (Figure 4A).
SOCS1 has been known to inhibit JAK phosphoryla-
tion and subsequent binding, phosphorylation and acti-
vation of STATs. In the absence of SOCS1, type I IFN-
induced STAT1 activation is prolonged, and the anti-
viral and pro-inflammatory effect of these elements are
amplified [21,22]. As SOCS1 is suppressed by miR-155,
we speculated that miR-155 over-expression in human
hepatoma cells may play a role in JAK/STAT signaling.
As expected, p-STAT1 and p-STAT3 were constitutively
activated in HepG2 cells over-expressing miR-155 (Fig-
ure 4C, E). Similar results were observed in H7402 cells
(Figure 4F, G). These findings revealed that miR-155
post-transcriptionally regulated SOCS1 expression and
activated JAK/STAT signaling in human hepatoma cells.
Augmented type I IFN signaling by miR-155 over-
expression in human hepatoma cells
We examined type I IFN production in HepG2 cells and
found no significant difference in the mRNA levels of
Figure 2 miR-155 slightly increased the growth of human
hepatoma cells. (A) HepG2 and HepG2-miR155 cell growth were
determined by MTT assay. (B) HepG2 cells were transfected with 50
nM miR-155 mimics or control RNA followed by MTT assay 6 h after
transfection. These experiments were repeated at least 3 times.
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Page 3 of 11Figure 3 Over-expression of miR-155 enhanced IFN-Inducible genes expression in human hepatoma cells. HepG2 cells, HepG2-miR155
cells or HepG2 cells and H7402 cells transfected with 50 nM miR-155 mimics/control RNA were harvested. As described in Materials and
Methods, (A, C) RT-PCR analysis was performed to evaluate IFN-inducible genes. (B, D) Relative density analysis of IFN-induced gene mRNA levels.
(E, F) RT-PCR analysis and relative density analysis of IFN-inducible genes in H7402 cells 48h after transfection. (G, H) Western blot analysis of
ISG15 levels in HepG2 cells treated as above. One representative of three independent experiments was shown. (*p < 0.05 by comparison with
control cells).
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expressed (data not shown). We next analyzed the
expression of IFN inducible antiviral genes in response
to the treatment of IFN-a2a.A ss h o w ni nF i g u r e5 A
and 5B, antiviral genes expressed in HepG2 cells treated
with miR-155 mimics were higher than that in control
cells. Moreover, the expression of SOCS1 was decreased,
while the expression of p-STAT1 and p-STAT3 were
increased in HepG2 cells transfected with miR-155
mimics after IFN-a2a treatment (Figure 5C and 5D).
These data suggested that over-expression of miR-155
could promote type I IFN signaling and increase IFN-
inducible antiviral gene expression in human hepatoma
cells.
Over-expression of miR-155 inhibited HBV in human
hepatoma cells
Human hepatitis B virus (HBV) induces hepatitis and is
closely associated with the incidence of human hepa-
toma cancer [9]. HBV was shown to be very efficient at
inhibiting the IFN signaling pathway [23-25]. So, we
further assessed whether over-expression of miR-155
could attenuate HBV infection. PAAV/HBV1.2 plasmid
and miR-155 mimics, or control RNA were
Figure 4 miR-155 post-transcriptionally inhibited SOCS1 and activated JAK/STAT signaling pathway in human hepatoma cells.( A )
Analysis of SOCS1 mRNA levels by RT-PCR. Total RNA was extracted from HepG2 and HepG2-miR155 cells, and HepG2 cells transfected with 50
nM miR-155 mimics or control RNA. (B) SOCS1, (C) p-STAT1 and p-STAT3 protein levels in cells above were tested by western blot analysis. (D, E)
Relative density analysis of the IFN-induced gene protein levels. (F) Western blot analysis of ISG15, SOCS1, p-STAT1 and p-STAT3 protein levels in
H7402 cells were performed 48h after transfection. (G) Relative density analysis of the IFN-induced gene protein levels in H7402. One
representative of three independent experiments was shown.
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HBV X gene (HBx) were examined by RT-PCR. As
shown in Figure 6A and 6B, HBx level was reduced ~
12% in HepG2 cells transfected with miR-155 mimics
compared with HepG2 cells transfected with control
RNA (P < 0.05) (Figure 6B right), but there was no sig-
nificant difference between HepG2 and HepG2-miR155
cells (Figure 6B left). One explanation for this result is
that the level of miR-155 in HepG2 cells transfected
with miR-155 mimics was much higher than that in
HepG2-miR155 cells (Figure 1A and 1B), so we specu-
lated that the antiviral effect of miR-155 depended on
its level.
Since miR-155 affect type I IFN signaling pathway, we
further addressed whether miR-155 could change the
anti-HBV efficiency of exogenous IFN, but as shown in
Figure 6C and 6D, the levels of HBV X gene in HepG2
cells treated with miR-155 mimics or control RNA
showed no significant difference in the presence of IFN-
a2a. Type I IFN can inhibit HBV replication intensively
in some HBV-bore cell models based on HBV genome
transfection, but miRNA always shows more delicate
regulation on virus life cycle than that of siRNA which
directly degrade virus RNA. So, IFN-a2a may exert
much stronger controlling effects on HBV in hepato-
cytes than that of miR-155 itself. Taken together, these
results indicate that miR-155 exhibited mild anti-HBV
effect in human hepatoma cells.
Discussion
To date, only few publications reveal the roles of miR-
155 in viral infection. Viruses can utilize host miRNAs
as survival mechanisms, and even encode viral mimics
of host miRNAs. One such miR-155 mimic has been
found in Kaposi’s-sarcoma-associated herpesvirus
(KSHV) [7,26,27]. The infection of primary human B
lymphocytes with the Epstein-Barr virus (EBV) leads to
a sustained elevation of miR-155 expression and contri-
butes to EBV immortalization [28]. These studies sug-
gest that miR-155, encoded by viruses or upregulated by
viral infection, contributes to viral-mediated infection
via modulating different transcription factors and NF-B
components [14,29-31]. However, a recent research
reveals that miR-155 expression is also upregulated by
Figure 5 Augmented type I IFN signaling by miR-155 over-expression in human hepatoma cells. (A) HepG2 cells transfected with 50 nM
miR-155 mimics/control RNA were stimulated by 500 U/mL IFN-a2a for 12 h. RT-PCR analysis was performed to evaluate IFN-inducible genes.
(B) Relative density analysis of the IFN-inducible genes. (C) SOCS1, p-STAT1 and p-STAT3 protein levels in cells above were tested by western
blot analysis. (D) Relative density analysis of the signaling transduction protein levels in HepG2 cells. One representative of three independent
experiments was shown.
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transfected into HepG2 and HepG2-miR155 cells, or 0.5 μg PAAV/HBV1.2 plasmid and 50 nM miR-155 mimics/control RNA were cotransfected
into HepG2 cells. 48 h later, RT-PCR analysis of HBV X gene (HBx) expression was performed. (B) Relative density analysis of HBx expression. (C)
0.5 μg PAAV/HBV1.2 plasmid and 50 nM miR-155 mimics/control RNA were cotransfected into HepG2 cells. 24 h after transfection, cells were
treated with IFN-a2a at the concentration of 500 U/mL for another 24 h, and then RNA was extracted and RT-PCR analysis of HBx expression
was performed. (D) Relative density analysis of HBx expression for (C). One representative of three independent experiments was shown. (*p<
0.05 by comparison with control cells).
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miR-155 feedback attenuates the viral replication
through enhancing type I IFN signaling by targeting
SOCS1 [32]. The biological function of miR-155 in
hepatoma cells is still unclear.
HBV is a hepatotropic, enveloped DNA virus, causes
acute and always chronic HBV infection and leads to
hepatoma fibrosis, cirrhosis and eventually hepatocellu-
lar carcinoma [9]. Recent studies have revealed the role
of several miRNAs in intricate network of hepatocyte-
HBV interactions. Early in 2007, Ai-Guang Guo group
firstly predicted that HBV may encode one miRNA [33],
but miRBase didn’t accept it as a formal member until
now. Many host miRNAs were forecasted to bind to
both HBV genome and host gene by different labora-
tories [34-36]. By the end of the year 2010, miR-199a-3p
and miR-210 were found to suppress HBsAg expression
by directly targeting the HBV S protein coding region
and pre-S1 region, respectively [37]; miR125a-5p was
then shown to interfere with the viral translation, down-
regulating the expression of the surface antigen [38],
while miR-1 increases HBV transcription by upregulat-
ing farnesoid X receptor a (FXRA), a nuclear receptors
binding to the HBV core promoter and regulating HBV
transcription and replication. Here, we showed that
miR-155 also exhibited mild anti-HBV effect in human
hepatoma cells through promoting JAK/STAT signaling
pathway and enhancing innate antiviral immunity. Our
work reveals a new intricate physiological interplay
between miRNAs and HBV replication.
Many evidence shows that miR-155 is over-expressed
in a number of neoplastic diseases and plays a signifi-
cant role in the process of carcinogenesis, acting as an
oncomir [39-42]. In this paper, we found that miR-155
expression was very low in HepG2 cells. Though ectopic
expression of miR-155 could promote HepG2 cell prolif-
eration, the extent was much weaker than that in other
cell lines, such as breast cancer cells [20], which is
favorable for miR-155 to be used in antiviral therapeu-
tics without significantly affecting host cell proliferation.
These findings indicated that miR-155 play different
roles in diverse cells.
In this study, we notice that not all the IFN-induced
genes are equally induced by miR-155 over-expression.
Since they are all regulated by JAK/STAT signaling and
the downstream of type I IFN signaling pathway [43],
there must be some other mechanisms to regulate their
expression. Though expressions of MxA and ISG15
were elevated by miR-155, their levels were only
increase by less than 50% (Figure 3B and 3D), and HBx
was only reduced by ~10% (Figure 6B), which is differ-
ent from a recent report, where VSV replication was lar-
gely suppressed by miR-155 in macrophages [32]. This
may due to the difference of host cells and viruses. The
potency of one miRNA in hepatocytes would be rather
weaker than that in lymphocytes, and HBV has its own
properties.
Overall, although the anti-HBV effect mediated by
miR-155 is lower compared with its anti-VSV effect in
macrophages, it might benefit to anti-HBV when com-
bine with other antiviral therapeutics. The detail
mechanisms will be further investigated in the future.
Conclusions
miR-155, as a positive regulator of JAK/STAT signaling
by targeting SOCS1, increases the expression of IFN-
inducible antiviral genes and enhances innate antiviral
immunity in human hepatoma cells. Further more, over-
expression of miR-155 exhibited mild anti-HBV effect in
human hepatoma cells.
Materials and methods
Cell line and cell culture
Human hepatocellular carcinoma cell lines HepG2 and
H7402 conserved in our laboratory, were cultured in
DMEM (GIBCO/BRL, Grand Island, N.Y. USA) contain-
ing 10% FBS in a humidified incubator with 5% CO2 at
37°C.
Vector construction
Total genomic DNA was extracted from HepG2 cells
using Genomic DNA Extraction Kit purchased from
Sangon Biotech (Shanghai, China) according to the
manufacturer’s instructions. The miR-155 expression
cassette containing the human miR-155 hairpin
sequence and flanking regions was amplified from the
genomic DNA using the pri-miR-155 primers (Table 1).
The cassette was then inserted into an expression vector
(pcDNA3). The resulting construct was termed
pcDNA3-hsa-miR-155. The construct was confirmed by
DNA sequencing. PAAV/HBV1.2 consists of a greater
than genome-length HBV fragment that encodes all the
proteins of HBV including large, middle and small sur-
face proteins, polymerase protein, X protein, and core
and pre-core proteins. It can initiate HBV replication
after being transfected into hematoma cell lines [44].
RNA oligonucleotide and cell transfection
miR-155 mimic (dsRNA oligonucleotides), used for the
over-expression of miR-155 in hepatoma cells, and
negative control RNA (dsRNA oligonucleotides), used
as the matched control, were purchased from Shanghai
GenePharma Co., Ltd (Shanghai, China). Transfection
was performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. For transfection of the RNA oligonucleo-
tides, 50 nM miRNA mimics or control RNA were
used.
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pcDNA3-hsa-miR-155 plasmid (0.4 μg) were transfected
into HepG2 cells, and then 200 μg/mL G418 (GIBCO/
BRL) was added 48 h after transfection, and the cells
stably over-expressing miR-155 were selected for two
weeks until clones form.
Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) assay
RNA was extracted from HepG2 cells (5 × 10
5)b yT r i -
zol Reagent (Invitrogen, Carlsbad, CA, USA) according
to the protocol provided by the manufacturer. The con-
centration and quality of the extracted RNA were deter-
mined by measuring light absorbance at 260 nm (A260)
at a ratio of (A260/A280). Total RNA was reverse tran-
scribed to cDNA and standard PCR reaction was per-
formed in a total volume of 25 μl as described
previously [45]. The PCR products were electrophoresed
on 2% agarose gels and the relative light intensities of
bands were analyzed by AlphaEaseFC software. The
PCR primers and their product lengths are listed in
Table 1 and were synthesized by the Beijing Genomics
Institute (Beijing, China).
Quantitative reverse transcription-PCR assay
The miR-155 level was quantified by quantitative reverse
transcription-PCR (qRT-PCR) using specific Bulge-
Loop™ miRNA qRT-PCR Primer purchased from
Guangzhou Ribobio (Guangzhou, China) with U6 small
nuclear RNA as an internal normalized reference.
Cell proliferation assay
All cellular growth assays were performed in 96-well
plates (6 × 10
3 cells/well). HepG2 cells were transfected
with 50 nM miR-155 mimics or control RNA. Four
hours after transfection, equal numbers of viable cells
were seeded in 96-well plates and incubated for indi-
cated time. Next, 20 μl MTT (10 mg/ml, Sigma, St
Louis, MO, USA) solution was added to each well and
the plates were incubated for additional 4 h at 37°C.
After centrifugation, MTT solution was then removed,
and 200 μl dimethyl-sulfoxide (DMSO; Sigma, St Louis,
MO, USA) was added to each well to solubilize the for-
mazan crystals. Absorbance was then read at a wave-
length of 570 nm on a scanning multiwell
spectrophotometer.
Western blot
Cells were harvested 48 h after seeded or transfection
and homogenized in lysis buffer (30 mM Tris, pH 7.5,
1 5 0m Ms o d i u mc h l o r i d e ,1m MP M S F ,1m Ms o d i u m
orthovanadate, 1% Nonidet P-40, and 10% glycerol) at 4°
C, vortexed, and centrifuged at 13,000 g at 4°C for 30
min. The supernatants were mixed in Laemmli loading
buffer, boiled for 5 min, and then subjected to SDS-
PAGE. After electrophoresis, proteins were transferred
onto nitrocellulose membranes and blotted against pri-
mary Abs for 12 h. Membranes were washed with 0.1%
(v/v) Tween 20 in TBS and incubated with a 1:2000
dilution of HRP conjugated secondary Abs for 1 h. Pro-
tein bands were visualized by Immobilon Western Che-
miluminescent HRP Sbustrate (Millipore Corporation,
Billerica, U.S.A). Antibodies for SOCS1, ISG15 and p-
STAT1 were from Cell Signaling Technology (New Eng-
land BioLabs Inc.); antibody for phospho-STAT3 was
from Bioworld Technology, Inc. (Minneapolis, Minne-
sota, USA); and antibody for b-actin was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analyzes
All data are expressed as mean±SD and accompanied by
at least three distinct experiments. Statistical analysis
Table 1 Primers used for RT-PCR reactions
Transcripts Product size(bp) Sequences (5’-3’) Tm(°C) PCR cycle
b–actin 540 GTGGGGCGCCCCAGGCACCA
CTCCTTAATGTCACGCACGATTTC
60°C 28 cycles
SOCS1 301 CACGCACTTCCGCACATTCC
TCCAGCAGCTCGAAGAGGCA
55°C 35 cycles
MxA 581 ACCAGCTGAGCCTGTCCGAAGCCC
CCGGACCATATCCGTCACGGTG
60°C 35 cycles
ISG15 294 GGTGGACAAATGCGACG
ATGCTGGTGGAGGCCCTTAG
60°C 28 cycles
OAS-1 356
454
ACACATTTCAACACAGCCCA
TGCAGGTCCAGTCCTCTTCT
60°C 35 cycles
APOBEC3B 981 GTTTGTATCCTGGACCCCCT
GAGATGGTGGTGAACGGTCT
60°C 30 cycles
HBx 250 CCGTCTGTGCCTTCTCATCTGC
CCTCCGACATCCGTATTTAACCA
60°C 28 cycles
pri-miR-155 307 AGGTGGCACAAACCAGGAA
GTTGAACATCCCAGTGACCAG
58°C 38 cycles
Su et al. Virology Journal 2011, 8:354
http://www.virologyj.com/content/8/1/354
Page 9 of 11was performed using SPSS software (version 10.0; SPSS
Inc., USA) and p < 0.05 were considered statistically
significant.
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